UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000004729 |
|---|---|
| Receipt number | R000005630 |
| Scientific Title | Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancer |
| Date of disclosure of the study information | 2011/01/01 |
| Last modified on | 2015/04/21 08:39:15 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancer
Acronym
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin
Scientific Title
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancer
Scientific Title:Acronym
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin
Region
| Japan |
Condition
Condition
unresectable or recurrent gastric cancer
Classification by specialty
| Gastroenterology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
In the phase I trial, primary objective is to estimate the maximum tolerated dose(MTD) and recommended dose(RD) of Paclitaxel and cisplatin with S-1 chemoradiotherapy for unresectable / recurrent gastric cancer.
In the phase II trial, primary objectives is to evaluate the efficacy and safety.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Phase I,II
Assessment
Primary outcomes
[phase I]
Estimate the maximum tolerated dose (MTD) and recommended dose (RD) of PTX and CDDP
[phase II]
Response rate
Key secondary outcomes
[phase II]
Overall Survival, Progression Free Survival, Adverse events
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
S-1, CDDP and PTX combination chemotherapy is conducted. The S-1 is administered for 14 days followed by 14 days rest according to body surface area. CDDP and PTX is administered intravenously in each dosage of level at day 1 and 15.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1)confirmed gastric cancer by endscopic biopsy
2)inoperable and recurrent gastric cancer
3)have measurable tumor region (preferable that patient have the target region which matched to RECIST guideline)
4)more than 10mm of longest diameter by spiral computed tomography or more than 20mm of longest diameter by computed tomography.
5) No prior chemotherapy. Only the case who has passed six months or more since chemotherapy ended assumes is acceptable.
6) No prior radiotherapy. The case who has received radiotherapy for non target region is acceptable.
7) age: >=20 and <75
8) Performance status 0 or 1
9) Expected to survive more than 3 months
10) sufficient function of important organs
1.WBC: >=4,000/mm3 and <=12,000/mm3
2.Neu: >=2000/mm3
3.Platelet: >=100,000/mm3
4.sT.bil: 1.5mg/dl
5.AST, ALT: 2.5 times of normal range in each institute
6.Haemoglobin: >=9.0g/dL
7.Serum creati: <=1.5mg/dL
8.Ccr: >=60 ml/min/body
11) possible to oral intake
12) written informed consent
Key exclusion criteria
1) with heart disease needed to treat (ex. ischemic cardiac disease, arrhythmia)
Left ventricular hypertrophy according to high blood pressure, slight left ventricle load, slight right bundle branch block are acceptable.
2) Cardiac infarction that developed within six months
3) Cirrhosis and hepatitis of briskness
4) Breathing difficulties that require oxygen administration by interstitial pneumonia and lungs fiber syndrome, etc.
5) Gut freshness hemorrhage that repeatedly requires transfusion
6) with clinically important mental disorder need to treat or treating with mind drug
7) with uncontrollable diabetes mellitus
8) with intestinal obstruction and sub-intestinal obstruction
9) infection with fever or doubt it
10) Double cancer of briskness
11) brain metastasis with symptom
12) Acute inflammatory disorder
13) Peripheral neuropathy
14) history of severe drug anaphylaxis
15) history of severe anaphylaxis to drug included Cremohor EL or Stiffening castor oil
16) pregnant woman, breast-feeding woman, and possibility of pregnancy
17) doctor's decision not to be registered to this study
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tsunehiro Takahashi |
Organization
School of Medicine, Keio University
Division name
Department of surgery, Department of internal medicine
Zip code
Address
35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
School of Medicine, Keio University
Division name
Department of surgery
Zip code
Address
TEL
Homepage URL
tsunehiro-t@a8.keio.jp
Sponsor or person
Institute
School of Medicine, Keio University
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 01 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2009 | Year | 09 | Month | 28 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 10 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2010 | Year | 12 | Month | 15 | Day |
Last modified on
| 2015 | Year | 04 | Month | 21 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005630
